

# **Pharma Regulatory Affairs**

28 - 29 June 2018 | Mandarin Orchard Hotel, Singapore

# **Key Learning Outcomes**

- Current priorities in regulatory compliance across the Globe and Asian Markets
- Understand the approval, submission, registrations processes and differences in requirements for R&D products and generics
- Understanding markets and exclusivity what is being regulated
- Regulations and procedures for biosimilars and generics
- Discuss harmonisation initiatives including ASEAN opportunities
- Discover general country specific and regional requirements
- Regulatory strategies for OTC products
- Pharmacovigilance and individual country requirements
- Tackling supply chain, packaging and labelling regulations
- Emerging regulatory issues in the digitalisation of Pharma

### **Dedicated Case Studies and Exercises on:**

- ASEAN generic launch
- Asian OTC products
- European /US opportunity

# **Who Should Attend**

### Personnel from

- Analytical Research and Development
- Clinical Development
- Quality Assurance
- New Business Development Departments
- Regulations and Compliance
- Market Access, Market Development and Marketing professionals

### **Course Director**

Peter Wittner, B.Sc., is an independent consultant specialising in the commercial aspects of generics with nearly 40 years' pharmaceutical experience. The major part of this has been spent in the generic industry. He was Managing Director for the UK subsidiary of the Indian generic leader Ranbaxy, having joined them to set up the business before returning to consultancy work.

Before that, Peter had headed the European Sales & Marketing department of the UK generics companies Evans Medical and H.N. Norton, which later became part of IVAX and then Teva.

# Attend in a team and save more!

2+1 Offer!

**Offer!** See registration page for details!



Save up to 40% with Inhouse Training



Special Group Savings Available



All participants receive a Course Certificate



# **Pharma Regulatory Affairs**

### **About the Course Director**



Peter Wittner, B.Sc., is an independent consultant specialising in the commercial aspects of generics with nearly 40 years' pharmaceutical experience. The major part of this has been spent in the generic industry. He was Managing Director for the UK subsidiary of the Indian generic leader Ranbaxy, having joined them to set up the business before returning to consultancy work.

Before that, Peter had headed the European Sales & Marketing department of the UK generics companies Evans Medical and H.N. Norton, which later became part of IVAX and then Teva.

In the field of generics, Interpharm works with new market entrants on developing commercial strategies, compiling competitor intelligence, assisting in business development and gaining EU-GMP approval for companies outside the EU that are trying to enter the market. Peter has also assisted in generic product in- and out-licensing negotiations both in the EU and US markets. Recently, he has become increasingly involved in the field of biosimilars.

On the other side of the equation, Interpharm has also worked with originator companies that are looking at ways of defending their major brands from generic incursion or are themselves considering entry in to the field of generics.

Peter is a regular speaker at generic and biosimilars conferences, and runs workshops on generic and Biosimilars topics for various organisations as well as conducting training seminars. He has written a number of reports on generics industry topics and a series of reports for Decision Resources and other publishers. Originally based in north London, Peter has now relocated to Israel.

### About the course

Navigating through the complex environment of Pharma regulatory affairs to gain market access

up-to-date with current requirements Being understanding individual authority interpretation of quidelines is critical for all pharma companies. The challenge in Asia is the frequency of changing regulations and increasing time-lag for regulatory approval. These factors can significantly impact your time to market and bottom line.

The most crucial stage for a pharmaceutical company to launch a new drug is getting the regulatory approval. The process is tedious, time-consuming and often lacking clarity that doubles up the effort and time needed to launch a new drug. Asia poses a potential and vast market for pharmaceutical companies but the channel to launch a pharma product could be extremely complicated. Asian countries have their own regulatory structure that requires different norms for drug approval. A global pharmaceutical company needs to follow different regulatory process of each Asian country in order to launch one pharmaceutical product.

This unique seminar will take a practical approach and delve into the nuts and bolts of region's changing and complex regulatory landscape and enable you to formulate strategies to access and penetrate the Asian pharmaceutical market.

Key focus areas will include the approval, submission. registrations processes and differences in requirements for generics, brands, biosimilars and OTC drugs, regulatory harmonisation, pharmacoviligence and digitalisation.

# What Past Delegates Liked About our Pharmaceutical Courses

- "Exercises were useful and trainer is knowledgeable"
- Noor Aida Binti Jaafar, Head of Marketing & Specialty Care, CCM **Pharmaceutical**
- "Case Studies and the workshop activities really helped a lot and more
- Praveen Kumar, Senior Manager, Pharmaniaga
- "Informative & insightful. Had a chance to network and share discussion / cross learn from participants"
- Chng Kien Peng, Executive Director, Xepa-Soul Pattinson (S) Pte Ltd
- "The course is very relevant to my job. The case studies and the workshop activities really helped a lot and were practical."
- Avadhanula Yagna Praveen Kumar, Senior Manager Intellectual Property, Pharmaniaga BHD
- "Very informative. It covers all scopes under the topics"
- ~ Norliza Binti Abdullah Zawawi, Legal Assistant Manager, Pharmaniaga Berhad

### **IBC Asia Upcoming Related Events:**

#### **Pharma Pricing**

- Commercial and Regulatory Strategies


26 - 27 June 2018, Singapore

### **Pharmacon Asia 2018**

(18 - 21 September 2018, Singapore)

- · Pharmaceutical Regulatory Affairs Asia
- Pharma Market Access & Pricing Asia
- · Accelerating Clinical Trials in Asia
- · Digital Pharma Asia







Explanation of Timings: These times act as a guide and may be modified slightly on the depth of class discussion and whether assessments are being conducted.

**Course Programme:** This program is a guide and may be altered to better address participant requirements on a consensus basis.

### 2-DAY COURSE OUTLINE

### DAY ONE

### THE BACKGROUND - WHY DOES REGULATION EXIST?

- Why is registration necessary?
  - » History of regulatory requirements
  - » The Pharmacopoeia
  - » How Thalidomide changed everything
- History overview of how the regulations developed
  - » The main regulatory bodies who, what and how
  - » UK's CSM
  - » US FDA
  - » Europe the EMA
  - » Moves towards harmonisation ICH
- Overview of differences between requirements for R&D products and generics
  - » Hatch Waxman (US)
  - » European directives
    - \* EU definition of a generic
  - » Biosimilars simplified, but still complex

# UNDERSTANDING MARKETS AND EXCLUSIVITY – WHAT IS BEING REGULATED

- · Impact of patents and Data Exclusivity
  - » Europe quality, safety and efficacy
  - » Europe launching before patent expiry
  - Europe lauricriffig before patent expiry
     US challenging patents by filing an
  - ANDA
- » US what is Paragraph IV?
- What is data exclusivity?
- ASEAN considerations

» How do the national regulations compare?

#### **GENERICS AND BIOSIMILARS**

### UNDERSTANDING BIOSIMILARS REGULATIONS

- » Why the interest?
  - \* Hybrid products not originators, but not really generics
  - \* Markets and products
- \* Success stories
- » History of biosimilar regulatory procedures
  - \* Europe path finders
  - \* USA slow starters
  - \* ASEAN countries
  - \* India and China
- · Regulatory requirements for generics
  - » Relevant legislation US, Europe and key Asian markets in focus
  - » Impact of regulatory processes on the market
- Legislation -a bit more detail
  - » Hatch Waxman (US)
    - \* Why was it introduced?
    - \* Advantages for originators
    - \* Advantages for generics
  - » European directives
    - \* Removing the barriers
    - \* Generic definition
    - \* European reference product
- European Regulatory mechanisms

- » Centralised, DCP, MRP systems
  - \* Who reviews the dossier?
    - The different European bodies
- Bioequivalence
  - » What is it?
  - » Which reference products can be used
  - » CTD European style
- · Moves towards international harmonisation
  - » ICH purpose and aims
  - » From paper to CDs and on-line filing eCTD
    - \* The five modules:
      - Administrative information and prescribing information
      - 2. Common technical document summaries
      - 3. Quality
      - 4. Nonclinical study reports
      - 5. Clinical study reports

#### **BRAND TO OTC SWITCH**

- Why switch?
  - » Advantages
  - » Disadvantages
- Rules and regulations overview
  - » What can be switched?
  - » Are the rules uniform everywhere?
- Individual ASEAN country requirements
  - » Singapore, Malaysia, Indonesia and Philippines

**REVIEW OF DAY 1 TOPICS AND QUESTIONS** 

### **DAY TWO**

### **FOCUS ON ASEAN - PART 1**

**Guest Speaker: Vicky Han,** Senior Director, Policy Group Lead for Asia Pacific, Global Regulatory Affairs, **Janssen Asia Pacific,** Singapore

- Current priorities in regulatory compliance in APAC with focus on ASEAN countries
- Key areas of noncompliance, and frameworks to manage them
- Regulatory updates harmonization, new policy, clarity and speed in licensing, submission and approval in the region
- Recent Trend of Pharmaceutical Regulations
   Approvals, Submissions, Registrations,
   Pharmacovigilance, New Medicine
   Development, patient labelling
- eCTD and RPS APAC Progress in eSubmissions
- Accelerating Drug Approval in Asia -Overview of Time-Frames, Drug Registration Procedures, Opportunities and Challenges
- Regulatory strategies for OTC products -Registration, License, Compliance, Safety and Risk Control
- Accelerating Drug Approval in Asia: Time-Frames and Procedures
- · Whats next?

### FOCUS ON ASEAN - PART 2

- After registration ASEAN
  - » Pharmacovigilance monitoring safety
  - » Individual country requirements
- Variations
  - » Definitions and Types
    - \* What is needed?
- Pharmaceutical competition law
  - » What are the issues?
  - » ASEAN focus

# SUPPLY CHAIN, PACKAGING AND LABELLING


- Supply Chain regulations
  - » Counterfeit drugs
    - \* Overview of the problem how big is it?
    - \* Can you spot the fakes?
  - » Patent infringement not the same as counterfeiting
  - » EU FMD Falsified Medicines Directive
    - \* History
    - \* Aims
  - » US DSCA Drug Supply Chain Security Act
    - \* History
    - \* Aims
    - \* Deadlines


- » Solutions
  - \* Meet EPCIS (Electronic Product Code Information Services)
- » Asia a fragmented approach
- Measures to avoid counterfeiting
  - \* Serialisation
  - \* 2d barcodes -
  - Packaging text regulations
    - » What should the text show?
      - \* Prescription packs
      - \* OTC packs
    - » What should it not show?
- Leaflet texts
  - » What do they need to show?
  - » Physician's leaflet and patient leaflets the same but different
- How ASEAN countries view the issue

# PHARMA 4.0 – EMERGING REGULATORY ISSUES IN THE DIGITALISATION OF PHARMA

- Data protection and privacy
- Digital Health Technology (DHT) what does it mean?
- Other areas?

REVIEW OF DAY 2 TOPICS AND OPPORTUNITY FOR QUESTIONS







# **Pharma Regulatory Affairs**

### **5 EASY WAYS TO REGISTER**



MAIL the attached registration form with your cheque to IBC Asia (S) Pte Ltd

c/o Informa Regional Business Services

111 Somerset Road, TripleOne Somerset #10-05, Singapore 238164



Customer Service Hotline +65 6508 2401



Fax +65 6508 2407



register@ibcasia.com.sg



www.ibc-asia.com/pharmaregulatory

This label contains your priority booking code. To expedite registration, please do not remove label. If you have already received a copy of this brochure, we apologise. For reasons of confidentiality, your full particulars were not available to IBC Asia (S) Pte Ltd for deduplication prior to mail drop.

### **RESERVE YOUR PLACE TODAY!**

☐ Yes! I/We Will Attend Pharma Regulatory Affairs

28 - 29 June 2018 | Mandarin Orchard Hotel, Singapore

| FEE PER DELEGATE        | EARLY BIRD RATE  Register and Pay on or before 4 May 2018 | NORMAL RATE Register and Pay after 4 May 2018 |
|-------------------------|---|---|
| ☐ 2 Day Training Course | SGD 3,295 (SAVE SGD 200)                                  | SGD 3,495                                     |

### Register 2 Delegates & the 3rd attends FREE!

\*Applicable to Normal Rates only

- Special Group Discount pricing is applicable to groups of 2 or more delegates from the same organisation registering for the same event, at the same time.

| Delegate 1 Details  | Delegate 2 Details                        |
|---|---|
| Name: Dr/Mr/Ms  | •   |
| Job Title:  | Ib. Title.                                |
| Department  |   |
| Tel:  |   |
| Mobile No.:   | Mobile No.:                               |
| Email:  | Empile                                    |
| Delegate 3 Details  | Delegate 4 Details                        |
| Name: Dr/Mr/Ms  | Name: Dr/Mr/Ms                            |
| Job Title:  | Job Title:                                |
| Department  | Department                                |
| Tel:  | <u>Tel:</u>                               |
| Mobile No.:   | Mobile No.:                               |
| Email:  | Email:                                    |
|   | Please photocopy for additional delegates |
| Who is Head of your Department?   |   |
| Who is Head of Training?  |   |
| Who is Head of Training?  |   |
| Company Information   |   |
|   | Main Business/Activity:                   |
| Company Information   | Main Business/Activity: Postal Code:      |
| Company Information Company Name: Address:  Payment Method (Please tick:) |   |

#### HOTEL INFORMATION

Mandarin Orchard Singapore, by Meritus

333 Orchard Road, Singapore 238867 Tel: +65 6831 6062 | Fax: +65 6737 3130

Mobile No.: +65 8298 9442 Contact Person: Tan Ai Li

(Assistant Director Of Business Development, Catering Sales) Email: aili.tan@meritushotels.com

Website: www.meritushotels.com

#### **PAYMENT TERMS**

Payment must be received 10 business days prior to the event. To take advantage of discounts with an expiry date, registration <u>and payment</u> must be received by the cut-off date.

- Payment by bankers draft or cheque in S\$ or US\$ should be made in favour of "IBC Asia (S) Pte Ltd" and mailed to: IBC Asia (S) Pte Ltd c/o Informa Regional Business Services
  111 Somerset Road, TripleOne Somerset #10-05
  Singapore 238164

Attn: The Accounts Receivable Team

- Payment by bank transfer in S\$ or US\$ made payable to: IBC Asia (\$) Pte Ltd A/C No.:147-059513-001 (\$\$)
- A/C No.:260-457866-178 (US\$)
  The Hongkong and Shanghai Banking Corporation Limited 21 Collyer Quay, HSBC Building

Singapore 049320
Bank Swift Code: HSBCSGSG
Bank Code: 7232

Payment by Credit Card (AMEX, VISA or MasterCard). The best way to pay by credit card is through our secure portal built into the website. To pay by phone please indicate the contact name and details below and our Customer Services Team will call within 24 hours to take payment. Please do not send credit card information by email.

### **CANCELLATIONS / SUBSTITUTION**

Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must be received in writing at least 10 business days before the start of the event, to receive a refund less 10% processing fee per registration. The company regrets that no refund will be made available for cancellation notifications received less than 10 business days before the event

#### **IMPORTANT NOTE**

Please quote the name of the delegate, event title and invoice number on the advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts. Please fax your payment details (copy of remittance advice, cheque or draft to +65 6508 2407).

Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC assumes no further liability or obligation, beyond the refund of the paid registration fee, in the event of postponement or cancellation by IBC.

### **DATA PROTECTION**

The personal information entered during your registration/order, or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Occasionally, your details may be obtained from or shared with external companies who wish to communicate with you offers related to your business activities. If you do not wish your details to be used for this purpose, please confact our Database Department at Email: database@ibcasia.com.sg, Tel: +65 6508 2400 or Fax: +65 6508 2408.

2001 REG NO.



Department:

Email:



Credit card contact:

P40077

Direct phone number: \_